Genscript Biotech (HKSE:01548) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Genscript Biotech's Capital Expenditure for the six months ended in Dec. 2023 was HK$-184.30 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$-1,434.65 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Genscript Biotech Capex-to-Operating-Income Historical Data

The historical data trend for Genscript Biotech's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Capex-to-Operating-Income Chart

Genscript Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

Genscript Biotech Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Operating-Income	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Genscript Biotech's Capex-to-Operating-Income

For the Biotechnology subindustry, Genscript Biotech's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genscript Biotech's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's Capex-to-Operating-Income falls into.

Genscript Biotech Capex-to-Operating-Income Calculation

Genscript Biotech's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-1231.707)	/	-3116.657
	=	N/A

Genscript Biotech's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-184.303)	/	-1434.645
	=	N/A

Genscript Biotech (HKSE:01548) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Genscript Biotech Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech (HKSE:01548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Executives

Wang Luquan	2401 A concert party to an agreement to buy shares
Wang Ye	2101 Beneficial owner
Zhang Fangliang	2401 A concert party to an agreement to buy shares
Huang Lili	2202 Interest of your spouse
Hu Zhiyong	2201 Interest of corporation controlled by you
Jin Weihong	2201 Interest of corporation controlled by you
Genscript Corporation	2101 Beneficial owner
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Gns Holdings Limited	2101 Beneficial owner
Hillhouse Capital Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd.	2102 Investment manager

Genscript Biotech (HKSE:01548) Headlines

No Headlines